Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Arcadia Biosciences (RKDA) over the last 5 years, with Q3 2025 value amounting to $1.4 million.

  • Arcadia Biosciences' Shares Outstanding (Diluted Average) rose 59.59% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 59.59%. This contributed to the annual value of $1.4 million for FY2024, which is 1021.63% up from last year.
  • Latest data reveals that Arcadia Biosciences reported Shares Outstanding (Diluted Average) of $1.4 million as of Q3 2025, which was up 59.59% from $1.4 million recorded in Q2 2025.
  • Arcadia Biosciences' 5-year Shares Outstanding (Diluted Average) high stood at $22.2 million for Q3 2021, and its period low was $532016.0 during Q4 2021.
  • Over the past 5 years, Arcadia Biosciences' median Shares Outstanding (Diluted Average) value was $1.4 million (recorded in 2023), while the average stood at $3.4 million.
  • In the last 5 years, Arcadia Biosciences' Shares Outstanding (Diluted Average) plummeted by 9744.9% in 2022 and then surged by 14487.81% in 2023.
  • Arcadia Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $532016.0 in 2021, then grew by 12.66% to $599389.0 in 2022, then soared by 106.37% to $1.2 million in 2023, then grew by 10.22% to $1.4 million in 2024, then grew by 0.63% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.